Azucena Aldaz Pastor

Dr. Azucena Aldaz Pastor


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2018 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
CCCarlos J. Chaccour
Carlos J. Chaccour
KNKija Ngha’bI
Kija Ngha’bI
GAGloria Abizanda
Gloria Abizanda
AIAngel Irigoyen
Angel Irigoyen
APAzucena Aldaz Pastor
Azucena Aldaz Pastor
GKGerry Killeen
Gerry Killeen
Mosquitoes that feed on animals can survive and mediate residual transmission of malaria even after most humans have been protected with insecticidal bednets or indoor residual sprays. Ivermectin is a widely-used drug for treating parasites of humans and animals that is also insecticidal, killing mosquitoes that feed on treated subjects. Mass administration of ivermectin to livestock could be particularly useful for tackling residual malaria transmission by zoophagic vectors that evade human-centred approaches. Ivermectin comes from a different chemical class to active ingredients currently used to treat bednets or spray houses, so it also has potential for mitigating against emergence of insecticide resistance. However, the duration of insecticidal activity obtained with ivermectin is critical to its effectiveness and affordability. A slow-release formulation for ivermectin was implanted into cattle, causing 40 weeks of increased mortality among Anopheles arabiensis that fed on them. For this zoophagic vector of residual malaria transmission across much of Africa, the proportion surviving three days after feeding (typical mean duration of a gonotrophic cycle in field populations) was approximately halved for 25 weeks. This implantable ivermectin formulation delivers stable and sustained insecticidal activity for approximately 6 months. Residual malaria transmission by zoophagic vectors could be suppressed by targeting livestock with this long-lasting formulation, which would be impractical or unacceptable for mass treatment of human populations.

1 September 2004 in Journal of Chromatography B
Verified
Journal Article
Closed access
LZL. Zufı́a
L. Zufı́a
APAzucena Aldaz Pastor
Azucena Aldaz Pastor
JGJ. Giráldez
J. Giráldez

12 April 2000 in Journal of Chromatography B: Biomedical Sciences and Applications
Verified
Journal Article
Closed access
JEJ Escoriaza
J Escoriaza
APAzucena Aldaz Pastor
Azucena Aldaz Pastor
CCC Castellanos
C Castellanos
ECEmiliano Calvo
Emiliano Calvo
JGJ Giráldez
J Giráldez

29 October 2003 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
IAIrene Aquerreta
Irene Aquerreta
APAzucena Aldaz Pastor
Azucena Aldaz Pastor
JGJoaquín Giráldez
Joaquín Giráldez
LSLuis Sierrasesúmaga
Luis Sierrasesúmaga

1 September 2020 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
LLLeire Leache
Leire Leache
IAIrene Aquerreta
Irene Aquerreta
APAzucena Aldaz Pastor
Azucena Aldaz Pastor
PMPablo Monedero
Pablo Monedero
AIAntonio Idoate
Antonio Idoate
AOAna Ortega
Ana Ortega

24 December 1999 in Journal of Chromatography B: Biomedical Sciences and Applications
Verified
Journal Article
Closed access
JEJ. Escoriaza
J. Escoriaza
APAzucena Aldaz Pastor
Azucena Aldaz Pastor
ECEmiliano Calvo
Emiliano Calvo
JGJ. Giráldez
J. Giráldez